

1. Record Nr.	UNINA9910678471803321
Autore	Calkins Tim
Titolo	Amgen : launching Repatha // Tim Calkins, Mike Harris
Pubbl/distr/stampa	London : , : Kellogg School of Management, , 2017
ISBN	1-5264-3112-2
Descrizione fisica	1 online resource : illustrations
Collana	SAGE Knowledge. Cases
Disciplina	616.12
Soggetti	Heart - Diseases - Treatment - United States Hypercholesteremia
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Originally published in Calkins, T., & Harris, M. (2017). Amgen: Launching Repatha. 5-416-759. Evanston, IL: Kellogg School of Management at Northwestern University.
Sommario/riassunto	In March 2015, Amgen is preparing for the launch of Repatha, a new molecule that has demonstrated a remarkable ability to treat high cholesterol. Through a series of clinical trials, Amgen has proven that the molecule is both safe and effective for patients with high cholesterol. It also is effective for patients with familial hypercholesterolemia, a difficult-to-treat population that has exceptionally high levels of cholesterol. Amgen expects the FDA to approve the molecule before the end of the year. Now, the Repatha team has to develop a revenue forecast.